Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Barclays Global Healthcare Conference  (Live)
03/10/15 at 8:30 a.m. ET
Webcast ImageWebcast
Q4 and Full Year 2014 AtriCure, Inc. Earnings Conference Call (Replay)
02/23/15 at 4:30 p.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Leerink Global Healthcare Conference (Replay)
02/12/15 at 1:00 p.m. ET

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$17.47 - 0.291.63%71,378
Previous CloseToday's OpenIntraday HighIntraday Low
$17.76$17.65$17.70$17.38
Exchange: NASDAQ (US Dollar)
03/03/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
02/27/15
Download Documentation Investor Presentation
10/30/14
Download Documentation Q3 Earnings Call Transcript
04/11/14
Download Documentation 2013 Annual Report

All Recent News

DateTitle 
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
02/24/15First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study
The collaborative study between cardiac surgeons and electrophysiologists to deliver innovative solutions and new treatment options for Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced the first two patients have been enrolled and ... 
Printer Friendly Version
02/23/15AtriCure Reports Fourth Quarter and Full Year 2014 Financial Results
2014 revenue of $107.5 million – up 31.2% 2014 U.S. sales of $80.2 million – up 28.7% 2014 International sales of $27.3 million – up 39.2%; 39.8% constant currency Fourth quarter 2014 revenue of $29.4 million – up 34.4% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and l... 
Printer Friendly Version
02/02/15AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financi... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
02/24/15First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study
The collaborative study between cardiac surgeons and electrophysiologists to deliver innovative solutions and new treatment options for Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced the first two patients have been enrolled and ... 
Printer Friendly Version
02/23/15AtriCure Reports Fourth Quarter and Full Year 2014 Financial Results
2014 revenue of $107.5 million – up 31.2% 2014 U.S. sales of $80.2 million – up 28.7% 2014 International sales of $27.3 million – up 39.2%; 39.8% constant currency Fourth quarter 2014 revenue of $29.4 million – up 34.4% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and l... 
Printer Friendly Version
02/02/15AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financi... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
03/10/15 
8:30 a.m. ET
AtriCure, Inc. at Barclays Global Healthcare Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.